Webinar: Global Clinical Research Leaders Address Rescue Study Challenges

Pharm-Olam’s Oleksandr Laroshkevych, M.D., Ph.D. hosted an interactive webinar on the implications of failing or stalled clinical trials.

NOVEMBER 1, 2016

Global clinical research experts Yamin “Mo” Khan, Ph.D., and Oleksandr Iaroshkevych, M.D., Ph.D. will host an interactive public seminar on the implications of failing or stalled clinical trials. The forum, entitled, “The Do’s and Don’ts of Study Transfer,” will be held at 11 a.m. on Thursday, November 10 via webinar.

 “On average, delays in clinical research cost treatment developers $8 million per day,” explained Dr. Khan, Executive Vice President of Clinical Development at Pharm-Olam International Ltd. Dr. Khan, who will moderate the webinar, added, “When you combine tight deadlines, the transfer of study ownership, and the intense regulatory oversight required in these trials, a recovery roadmap is critical to overcome obstacles and ensure success.”

Dr. Khan will be joined by subject matter expert Dr. Iaroshkevych. An M.D. and Ph.D., Dr. Iaroshkevych has 15 years of clinical research experience, 10 of which were dedicated to project management. Dr. Iaroshkevych has worked in a number of therapeutic areas in different stages of clinical trial programs across all continents. He currently serves as Associate Director, Project Management at Pharm-Olam International Ltd.

Pharm-Olam International, which operates in more than 60 countries worldwide, offers end-to-end support for Phase I-IV clinical trials. The organization boasts recent experience in over 75 rescue studies, ranging from complete study takeover to supplemental support services. The guidance provided in the webinar will include numerous examples from the Pharm-Olam team’s rescue study experience.

The webinar is free and open to the public.

About Pharm-Olam International Group

Pharm-Olam International is a multinational Contract Research Organization (CRO) offering comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines, making clinical research as Easy As I, II, III, IV™. For further information about Pharm-Olam, please visit www.pharm-olam.com.

Share this: